425: VERAXA Biotech and OmniAb Announce Co-discovery Alliance for Novel Bispecific Antibody Drug Conjugate Program

VERAXA Biotech, a proposed de-SPAC acquisition target of Voyager Acquisition Corp., partners with OmniAb to develop a novel bispecific antibody drug conjugate (bsADC) program targeting solid tumors.

Summary

• VERAXA Biotech AG and OmniAb, Inc. have entered into a co-discovery alliance to develop a novel bispecific antibody drug conjugate (bsADC) program targeting solid tumors.
• The collaboration combines OmniAb's antibody discovery solutions with VERAXA's proprietary antibody drug conjugate (ADC) linker technology.
• VERAXA will use OmniAb's technology to source human antibody leads and will establish the bsADC lead candidate using its linker technology.
• The resulting bsADC program will be jointly owned by both parties, and they will share future revenues from development, licensing, and commercialization.
• This is VERAXA's second major initiative in the past six months, following a radiopharmaceutical alliance late last year.
• VERAXA is currently involved in a definitive business combination agreement with Voyager Acquisition Corp., expected to result in VERAXA becoming a publicly traded company on NASDAQ.

Sentiment

Score: 7

Explanation: The announcement is positive due to the strategic partnership and potential for developing novel cancer therapies; however, it is tempered by the inherent risks in drug development and the uncertainties surrounding the de-SPAC transaction.

Positives

• The collaboration leverages complementary technologies from VERAXA and OmniAb.
• The bsADC program targets a significant unmet need in solid tumor treatment.
• Joint ownership and revenue sharing align the interests of both companies.
• VERAXA's strategic collaborations are a key part of its pipeline growth strategy.
• The de-SPAC transaction with Voyager Acquisition Corp. will provide VERAXA with access to public markets.

Risks

• The development of the bsADC program is subject to the risks and uncertainties inherent in drug development.
• The business combination with Voyager Acquisition Corp. is subject to various closing conditions and may not be completed.
• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially.

Future Outlook

VERAXA anticipates continued growth through strategic collaborations and advancement of its pipeline of antibody-based therapeutics, including bispecific ADCs and BiTAC formats, into clinical development and beyond; the company expects to become a publicly traded company listed on NASDAQ upon closing of the Business Combination Agreement with Voyager Acquisition Corp.

Management Comments

• Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA, stated that bispecific ADCs represent a powerful opportunity to address difficult-to-treat solid tumors.
• Christoph Antz noted that strategic collaborations will continue to be a mainstay in VERAXA's pipeline growth strategy.

Industry Context

This announcement reflects the growing trend of collaborations in the biotechnology industry to leverage complementary technologies and expertise for the development of novel therapeutics, particularly in the field of oncology; bispecific ADCs are an emerging class of cancer therapies that combine the specificity of antibodies with the cytotoxic activity of drug conjugates.

Comparison to Industry Standards

• The co-discovery alliance between VERAXA and OmniAb is similar to other partnerships in the pharmaceutical industry that aim to accelerate drug development by combining complementary technologies.
• Other companies involved in the development of ADCs include Seagen, ImmunoGen, and ADC Therapeutics.
• Bispecific antibodies are being developed by companies such as Amgen and Roche.
• The de-SPAC transaction is a common route for private companies to go public, but it carries risks related to market volatility and investor sentiment.

Stakeholder Impact

• Shareholders of Voyager Acquisition Corp. will be asked to vote on the proposed business combination with VERAXA.
• The collaboration could potentially benefit patients with solid tumors by providing new treatment options.
• Employees of both VERAXA and OmniAb may be impacted by the collaboration.

Next Steps

• VERAXA will initiate a novel bispecific antibody drug conjugate program.
• VERAXA will utilize OmniAb's suite of transgenic antibody discovery solutions to source high-quality human antibody leads.
• VERAXA will establish the bsADC lead candidate by applying its proprietary linker technology and conjugation routine.
• VERAXA will be responsible for preclinical validation.
• Voyager and VERAXA intend to file relevant materials with the SEC, including the Registration Statement, which will include a proxy statement/prospectus of Voyager.

Key Dates

Keywords

VERAXA Biotech, OmniAb, Voyager Acquisition Corp., bispecific antibody drug conjugate, bsADC, antibody drug conjugate, ADC, solid tumors, co-discovery alliance, de-SPAC, NASDAQ, pharmaceuticals, oncology